製品番号: HY-18777

KC7F2

24 Cited Publications

カスタマーレビュー

Based on 24 publication(s) in Google Scholar

KC7F2 is a potent hypoxia inducible factor-1 (HIF-1) pathway inhibitor with an IC₅₀ of 20 μM in LN229-HRE-AP cells, and with potential as a cancer therapy agent.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.36%
CAS 番号: 927822-86-4
分子式: C₁₆H₁₆Cl₄N₂O₄S₄
分子量:570.38

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

KC7F2 構造式

CAS 番号: 927822-86-4

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

KC7F2 is a potent hypoxia inducible factor-1 (HIF-1) pathway inhibitor with an IC₅₀ of 20 μM in LN229-HRE-AP cells, and with potential as a cancer therapy agent^[1].

IC₅₀ & Target

IC50: 20 μM (HIF-1, LN229-HRE-AP cells)^[1]

HIF/HIF Prolyl-Hydroxylase アイソフォーム固有の製品をすべて表示 :

体外実験

KC7F2 (15–25 μM; 0-72 hours) exhibits a clear dose-response cytotoxicity with an IC₅₀ value of approximately 15–25 μM depending on the cell lines, and this effect is more severe under hypoxic conditions^[1].
KC7F2 (0-80 μM; 6 hours) specifically reduces the protein levels of HIF-1α in a dose-dependent manner under hypoxic conditions; strongly decrease in HIF-1α levels at concentrations above 20 μM^[1].
KC7F2 does not affect the rate of HIF-1α protein degradation^[1].
KC7F2 inhibits HIF-1α protein synthesis but not its mRNA transcription^[1].
KC7F2 represses the phosphorylation of eukaryotic initiation factor 4E binding protein 1 (4EBP1)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:

MCF7 cells, LNZ308 cells, A549 cells, U251MG cells, LN229 cells
Concentration:

15–25 μM
Incubation Time:

0-72 hours
Result:

With cytotoxicity more pronounced in tumor cell lines as compared to normal cells.

Cell Viability Assay^[1]

Cell Line:

LN229 cells
Concentration:

6 hours
Incubation Time:

0 μM, 5 μM,7.5 μM,10 μM,15 μM,20 μM,30 μM,40 μM,60 μM,80 μM
Result:

Decreases HIF-1α protein levels in a dose-dependent manner.

化学情報

CAS 番号 927822-86-4
性状 Solid
分子量 570.38
分子式 C₁₆H₁₆Cl₄N₂O₄S₄
Color White to off-white
SMILES

O=S(C1=CC(Cl)=CC=C1Cl)(NCCSSCCNS(C2=CC(Cl)=CC=C2Cl)(=O)=O)=O
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (24)

All RT-PCRWBOthers

Sort by:

Journal Impact Factor

J Adv Res

Low temperatures enhance PM2.5-mediated mitochondrial dysfunction in the pig lung-intestinal axis, causing damage to the gut. [Abstract]

2026 May 3:S2090-1232(26)00380-2. PMID: 42086185
Redox Biol

Porcine epidemic diarrhea virus promotes viral replication via ROS/HIF-1α-mediated glycolysis. [Abstract]

2026 Feb:89:104008. PMID: 41512444
Acta Pharm Sin B

DDAH1 promotes neurogenesis and neural repair in cerebral ischemia. [Abstract]

2024 May;14(5):2097-2118. PMID: 38799640

KC7F2 purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2024 May;14(5):2097-2118. [Abstract]

Dual-luciferase reporter assay to detect the activity of Chat in NSCs stably transfected with the reporter construct pGL4.27 or pGL4.27-Chat. A HIF-1α inhibitor of KC7F2 was applied to NSCs from TG mice transfected with pGL4.27-Chat.
Cell Death Dis

Pyruvate dehydrogenase kinase 1 protects against neuronal injury and memory loss in mouse models of diabetes. [Abstract]

2023 Nov 7;14(11):722. PMID: 37935660

KC7F2 purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2023 Nov 7;14(11):722. [Abstract]

KC7F2 (40 μM). Western blot analysis of PDK1, p-S293-PDH, p-S300-PDH and PDH-E1 in each group.
J Neuroinflammation

Monocarboxylate transporter 1 promotes classical microglial activation and pro-inflammatory effect via 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 3. [Abstract]

2019 Nov 28;16(1):240. PMID: 31779643

KC7F2 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2019 Nov 28;16(1):240. [Abstract]

The overexpression efficiency of Lenti-MCT1 and quantification of the mRNA level of PFKFB3 in each group (n = 4 per group). KC7F2, an inhibitor of Hif-1α, 30 mM.
Acta Pharmacol Sin

Inhibiting von Hippel‒Lindau protein-mediated Dishevelled ubiquitination protects against experimental parkinsonism. [Abstract]

2023 May;44(5):940-953. PMID: 36357669

KC7F2 purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2023 May;44(5):940-953. [Abstract]

Representative immunoblots of HIF-1α, TH and β-actin in different groups of cells preincubated with/without KC7F2 (5 μM) for 1 h.
Mol Ther Oncolytics

Berberine inhibits carcinogenesis through antagonizing the ATX-LPA-LPAR2-p38-leptin axis in a mouse hepatoma model. [Abstract]

2022 Aug 5:26:372-386. PMID: 36090480
Mol Med

Aerobic exercise-induced HIF-1α upregulation in heart failure: exploring potential impacts on MCT1 and MPC1 regulation. [Abstract]

2024 Jun 12;30(1):83. PMID: 38867145
Free Radic Biol Med

LRRK2 deficiency protects the heart against myocardial infarction injury in mice via the P53/HMGB1 pathway. [Abstract]

2022 Oct:191:119-127. PMID: 36055602
Anal Chem

Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]

2025 Jun 3;97(21):11099-11109. PMID: 40401576
Pharmaceutics

Carrier-Free Hybrid Nanoparticles for Enhanced Photodynamic Therapy in Oral Carcinoma via Reversal of Hypoxia and Oxidative Resistance. [Abstract]

2024 Aug 27;16(9):1130. PMID: 39339168
J Ethnopharmacol

DiDang decoction improves mitochondrial function and lipid metabolism via the HIF-1 signaling pathway to treat atherosclerosis and hyperlipidemia. [Abstract]

2023 May 23:308:116289. PMID: 36822344

KC7F2 purchased from MedChemExpress. Usage Cited in: J Ethnopharmacol. 2023 May 23:308:116289. [Abstract]

KC7F2 upregulates the expression of Bcl2 and downregulates the expression of Bax in L02 cells.
Oncogenesis

Hypoxia induces an endometrial cancer stem-like cell phenotype via HIF-dependent demethylation of SOX2 mRNA. [Abstract]

2020 Sep 11;9(9):81. PMID: 32913192
J Cell Mol Med

HIF-1α is necessary for activation and tumour-promotion effect of cancer-associated fibroblasts in lung cancer. [Abstract]

2021 Jun;25(12):5457-5469. PMID: 33943003
FASEB J

Roxadustat Ameliorates Thoracic Aortic Dissection by Activating HIF-1α-Mediated Mitophagy to Inhibit Ferroptosis. [Abstract]

2026 Jun 15;40(11):e71979. PMID: 42201682
Front Biosci (Landmark Ed)

Increased expression of PD-L1 in endometrial cancer stem-like cells is regulated by hypoxia. [Abstract]

2022 Jan 17;27(1):23. PMID: 35090328
J Radiat Res Appl Sci

2026 May 1;19(2):102423.
Int J Biochem Cell Biol

Tumor necrosis factor α-induced protein 8-like-2 controls microglia phenotype via metabolic reprogramming in BV2 microglial cells and responses to neuropathic pain. [Abstract]

2024 Apr:169:106541. PMID: 38309648
BMC Anesthesiol

Propofol attenuated TNF-α-modulated occludin expression by inhibiting Hif-1α/ VEGF/ VEGFR-2/ ERK signaling pathway in hCMEC/D3 cells. [Abstract]

2019 Jul 9;19(1):127. PMID: 31288745

KC7F2 purchased from MedChemExpress. Usage Cited in: BMC Anesthesiol. 2019 Jul 9;19(1):127. [Abstract]

The hCMEC/D3 cells are treated with TNF-α, propofol, and Hif-1α inhibitor (KC7F2, 10 μM). Left side shows the image of a representative Western blot for Hif-1α, VEGF, p-VEGFR-2, p-ERK, ERK and occludin. Right side is the plot of normalized ratios of optical densities. β-actin is served as internal loading control.
Biochim Biophys Acta Gen Subj

Roxadustat ameliorates experimental colitis in mice by regulating macrophage polarization through increasing HIF level. [Abstract]

2024 Mar;1868(3):130548. PMID: 38158022
Gene

FSTL3 promotes colorectal cancer by activating the HIF1 pathway. [Abstract]

2025 Jun 20:954:149435. PMID: 40154584
SSRN

2026 Apr 11.
Research Square Preprint

2024 Jan 1.
Research Square Preprint

2021 Nov.

溶剤 & 溶解度

体外:

DMSO : ≥ 32 mg/mL (56.10 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7532 mL

8.7661 mL

17.5322 mL

5 mM

0.3506 mL

1.7532 mL

3.5064 mL

10 mM

0.1753 mL

0.8766 mL

1.7532 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (4.38 mM); Clear solution; Need ultrasonic

This protocol yields a clear solution of 2.5 mg/mL.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.38 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (273 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Narita T, et al. Identification of a novel small molecule HIF-1alpha translation inhibitor. Clin Cancer Res. 2009 Oct 1;15(19):6128-6136. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.7532 mL	8.7661 mL	17.5322 mL	43.8304 mL
	5 mM	0.3506 mL	1.7532 mL	3.5064 mL	8.7661 mL
	10 mM	0.1753 mL	0.8766 mL	1.7532 mL	4.3830 mL
	15 mM	0.1169 mL	0.5844 mL	1.1688 mL	2.9220 mL
	20 mM	0.0877 mL	0.4383 mL	0.8766 mL	2.1915 mL
	25 mM	0.0701 mL	0.3506 mL	0.7013 mL	1.7532 mL
	30 mM	0.0584 mL	0.2922 mL	0.5844 mL	1.4610 mL
	40 mM	0.0438 mL	0.2192 mL	0.4383 mL	1.0958 mL
	50 mM	0.0351 mL	0.1753 mL	0.3506 mL	0.8766 mL

Keywords

KC7F2

24 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

KC7F2

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Glutamine Metabolism Compound Library

Anti-Breast Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Targeted Diversity Library

Cancer Stem Cells Compound Library

Metabolic Enzyme Compound Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

MedChemExpress（MCE）の使用を引用している文献 KC7F2

HIF/HIF Prolyl-Hydroxylase アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (24)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

KC7F2

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Glutamine Metabolism Compound Library

Anti-Breast Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Targeted Diversity Library

Cancer Stem Cells Compound Library

Metabolic Enzyme Compound Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

MedChemExpress（MCE）の使用を引用している文献 KC7F2

HIF/HIF Prolyl-Hydroxylase アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (24)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

KC7F2 関連分類

HY-18777 関連分類